导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 23.37% | 27/354 |
| 近一周 | -3.12% | 335/362 |
| 近一月 | -2.11% | 112/362 |
| 近一季 | 12.95% | 53/362 |
| 近半年 | 22.02% | 14/358 |
| 近一年 | 58.45% | 5/349 |
| 近两年 | 45.78% | 58/314 |
| 近三年 | 87.13% | 11/246 |
| 成立以来 | 68.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.73% 29/360 |
22.29% 90/366 |
- - |
- - |
| 2025 | 32.41% 29/358 |
-9.72% 307/340 |
1.92% 217/348 |
19.29% 97/354 |
20.62% 1/358 |
| 2024 | -0.16% 229/329 |
5.69% 127/280 |
-2.36% 217/310 |
5.99% 145/318 |
-8.72% 268/329 |
| 2023 | 6.71% 96/275 |
-7.87% 185/205 |
8.60% 67/230 |
-10.87% 224/262 |
19.65% 1/276 |
| 2022 | -25.51% 120/201 |
-18.61% 119/153 |
-17.26% 128/164 |
6.14% 13/189 |
4.22% 138/202 |
| 2021 | -19.49% 82/150 |
-2.98% 277/312 |
-0.25% 246/328 |
-7.03% 200/358 |
-10.52% 130/151 |
| 2020 | 41.74% 10/103 |
-18.24% 209/280 |
40.65% 8/295 |
-0.86% 200/299 |
24.32% 14/305 |
| 2019 | 28.17% 25/88 |
23.88% 6/258 |
-3.15% 231/267 |
-13.24% 243/253 |
23.12% 1/266 |
| 2018 | -15.72% 59/79 |
- - |
- - |
0.43% 138/225 |
-23.99% 210/241 |
| 2017 | 30.76% 7/69 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2946 | 31.47% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3488 | 29.79% |
| 汇添富恒生生物科技ETF(QDII) | 1.1245 | 29.24% |
| 南方恒生生物科技ETF(QDII) | 1.1400 | 29.08% |
| 广发道琼斯石油指数美元现汇A | 0.4638 | 27.44% |
| 广发道琼斯石油指数美元现汇C | 0.4557 | 27.38% |
| 广发道琼斯石油指数(QDII-LOF)美元现汇E | 0.4568 | 27.33% |
| 南方恒生生物科技ETF发起联接(QDII)A | 1.2646 | 27.30% |
| 华夏恒生生物科技ETF发起式联接(QDII)C | 1.1472 | 27.25% |
| 汇添富恒生生物科技ETF发起式联接(QDII)C | 1.6358 | 27.22% |
| 易方达标普生物科技美元汇A VS. 建信富时100指数(QDII)人民币A(539003) |